Brainstorm Cell Therapeutics BCLI
OTC BCLI
$0.77 -0.02 (-2.53%)
As of: Oct 21, 2026 · 11:49 AM EDT

Brainstorm Cell Therapeutics (BCLI) Receivables (2010 - 2012)

Updated

Brainstorm Cell Therapeutics (BCLI) recorded Receivables of $449,000 in Q3 2012, up 21.7% from $369,000 a year earlier and up 6.7% from the prior quarter.

Analysis

Brainstorm Cell Therapeutics (BCLI) Receivables (2010 - 2012) Analysis & Trends

At the end of FY2011, Brainstorm Cell Therapeutics reported Receivables of $624,000, down 26.9% from FY2010.

  • Across earlier years, Receivables came in at $854,000 in FY2010.
  • Quarterly Receivables has ranged from $369,000 in Q3 2011 to $854,000 in Q4 2010 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $421,000 (Q2 2012), $482,000 (Q1 2012) and $624,000 (Q4 2011).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 13.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 12.49 Bn
10 Brainstorm Cell Therapeutics 8.50 Mn 8.43 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2012 449,000.00
Jun 30, 2012 421,000.00
Mar 31, 2012 482,000.00
Dec 31, 2011 624,000.00
Sep 30, 2011 369,000.00
Dec 31, 2010 854,000.00
API Access

Brainstorm Cell Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=BCLI&period=max&api_key=YOUR_API_KEY